Investigational drug · Phase 3
AR1001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimer Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "AR1001"
First trial start
2022
Dec 23, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AR1001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer Disease
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "AR1001" as an intervention, largest first.
- Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)Pivotal-lookingActive, not recruiting
AriBio Co., Ltd.Industry
NCT05531526 · 1,535 participants · Start Dec 23, 2022 · Primary completion Jun 29, 2026
Drug: AR1001; Placebo · For: Alzheimer Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Sun City, Arizona · 198 sites in all
- Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's DiseasePivotal-lookingCompleted
AriBio Co., Ltd.Industry
NCT03625622 · 210 participants · Start Apr 1, 2019 · Primary completion Dec 21, 2020
Drug: AR1001 10mg; Placebo and 1 more · For: Mild to Moderate Alzheimer's Disease
Sites: Banning, California; Sacramento, California; Santa Ana, California · 21 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease.
Greeley D, Nash M, Herskowitz B, et al. · J Prev Alzheimers Dis 2025
Also in development for Alzheimer Disease
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- AXS-05dextromethorphan-bupropionPhase 33 trials
Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- Combined metabolic activatorsPhase 32 trials
ScandiBio Therapeutics AB · Alzheimer Disease, Gout Disease
- DMB-IINN: Latrepirdine, DimebonPhase 32 trials
Bigespas LTD · Alzheimer Type Dementia, Alzheimer Disease, Dementia of Alzheimer Type
- XTR006[18F]MK 6240, FlorquinitauPhase 31 trial
Sinotau Pharmaceutical Group · Alzheimer Disease, Neurofibrillary Tangle
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.